Well first off, it’s a bio so it’s risky. BUT, that said, here’s the upside:
Read about these drugs in their pipeline. Groundbreaking.
https://oncternal.com/pipeline
Its peers were bought for over $2 billion. Onct’s market cap not even 500 mill right now. Consider that. Where is this company headed? It is the originator of ROR1. It owns royalties to a company that was bought out by MERCK last year. It owns all rights to any ROR1 chemical that comes out of UCSD (the inventors). It has other Pipeline drugs with accelerated status and orphan drug status.
Read about TK-216.
Check out the Q2 2021 milestones in this article. This is going to be either a huge failure or an amazing success.
It could all come crashing down but the more I SEE of what they’ve already done to help people with cancer (especially Ewing Sarcoma which attacks kids as well as what they’ve done to fight Breast Cancer which is one of the greatest threats to women) I’m actually proud to be part of this company.